NEW YORK (GenomeWeb) – Abbott reported today that third quarter sales in its Diagnostics business grew 5 percent year over year, driven by nearly 6 percent increases in both its point-of-care and core-lab diagnostics sales, but offset by a 1 percent decline in molecular diagnostics sales.

For the three months ended Sept. 30, Abbott reported overall Q3 revenues of $5.30 billion, up 3 percent from $5.15 billion in Q3 last year. The company beat the consensus Wall Street estimate of $5.29 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.